Sponsors (2)
Introduced February 10, 2026 by Elizabeth Warren · Last progress February 10, 2026
The bill seeks to restore competition and lower prices by prohibiting certain vertical ownership and giving regulators and private parties stronger enforcement tools, but it risks short-term care disruptions, higher compliance/penalty costs, and increased litigation and transaction uncertainty that could be passed on to patients and taxpayers.
Patients (including people with chronic conditions and Medicare beneficiaries) could pay lower drug and care prices and face fewer conflicts of interest when insurers/PBMs/wholesalers no longer steer care to affiliated providers.
Medicare beneficiaries and taxpayers could see reduced inflated Medicare Advantage payments if employed-physician documentation that raises MA payments is curtailed.
Hospitals, health systems, healthcare workers, state attorneys general, and private parties gain stronger enforcement tools because the FTC/DOJ (and state AGs/private litigants) can block anti-competitive vertical integrations and force divestitures, increasing competition in local markets.
Patients (especially those with chronic conditions and Medicare beneficiaries) could face disrupted continuity of care and temporary access problems if rapid forced divestitures or management transitions interrupt provider operations.
Taxpayers and insured consumers could face higher prices or reduced services if firms pass on large compliance, restructuring, or transaction costs from required divestitures (including short timelines) to customers.
Owners forced to divest face severe financial penalties in some cases (e.g., escrow penalties of ~10% monthly of profits) and short mandated divestiture timelines, which could impose heavy losses and discourage investment.
Based on analysis of 3 sections of legislative text.
Makes it illegal for the same company to own providers/MSOs and insurers/PBMs or providers/MSOs and drug/device wholesalers, and requires divestiture within one year with federal enforcement and penalties.
Prohibits a single company from owning both health care providers (or management services organizations) and either (a) insurers and pharmacy benefit managers (PBMs) or (b) prescription drug or medical device wholesalers. Companies that currently combine those businesses must divest one side within one year of enactment. The Federal Trade Commission and the Department of Justice Antitrust Division share enforcement authority, must issue divestiture milestone guidance within 30 days, and may seek court-ordered trustees, monetary escrow penalties, and other civil remedies for noncompliance.